Plus   Neg

AzurRx BioPharma Inc. (AZRX) Is Climbing On Phase 2 Study Results

AzurRx BioPharma Inc. (AZRX) announced Monday morning that it achieved both its primary and secondary endpoints in its Phase IIa trial of MS1819-SD.

AzurRx BioPharma has gapped open higher this morning and is now up 0.74 at $3.39 on above average volume. The stock has jumped to a 2 1/2 month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT